Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Atorvastatin/fimasartan - Boryung Pharmaceutical

Drug Profile

Atorvastatin/fimasartan - Boryung Pharmaceutical

Alternative Names: Akarb; Atorvastatin/BR-A 657; BR-1017B; Fimasartan/atorvastatin - Boryung Pharmaceutical

Latest Information Update: 28 Jul 2023

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Boryung Pharmaceutical
  • Class Antihyperlipidaemics; Antihypertensives; Fatty acids; Fluorobenzenes; Heptanoic acids; Pyrimidinones; Pyrroles; Small molecules
  • Mechanism of Action Angiotensin type 1 receptor antagonists; HMG-CoA reductase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Dyslipidaemias; Hypertension
  • Phase III Essential hypertension

Most Recent Events

  • 13 Jul 2023 Phase-III clinical trials in Essential hypertension (Combination-therapy) in South Korea (unspecified route) (NCT05930028)
  • 10 Jul 2023 Boryung Pharmaceutical plans a phase III trial for Essential hypertension and Hypercholesterolaemia (Combination therapy) in South Korea in July 2023 (NCT05930028)
  • 15 Jan 2018 Phase-III clinical trials in Hypertension and Dyslipidaemias in South Korea (PO)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top